Literature DB >> 24767708

Ovarian cancer.

Gordon C Jayson1, Elise C Kohn2, Henry C Kitchener3, Jonathan A Ledermann4.   

Abstract

Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated death. The disease typically presents in postmenopausal women, with a few months of abdominal pain and distension. Most women have advanced disease (International Federation of Gynecology and Obstetrics [FIGO] stage III), for which the standard of care remains surgery and platinum-based cytotoxic chemotherapy. Although this treatment can be curative for most patients with early stage disease, most women with advanced disease will develop many episodes of recurrent disease with progressively shorter disease-free intervals. These episodes culminate in chemoresistance and ultimately bowel obstruction, the most frequent cause of death. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Targeted treatments such as antiangiogenic drugs or poly (ADP-ribose) polymerase inhibitors offer potential for improved survival. The efficacy of screening, designed to detect the disease at an earlier and curable stage remains unproven, with key results expected in 2015.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24767708     DOI: 10.1016/S0140-6736(13)62146-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  621 in total

1.  Human papillomavirus capsids preferentially bind and infect tumor cells.

Authors:  Rhonda C Kines; Rebecca J Cerio; Jeffrey N Roberts; Cynthia D Thompson; Elisabet de Los Pinos; Douglas R Lowy; John T Schiller
Journal:  Int J Cancer       Date:  2015-10-27       Impact factor: 7.396

Review 2.  Role of the IL-33/ST2 receptor axis in ovarian cancer progression.

Authors:  Ning Liu; Jintong Chen; Yinghua Zhao; Mingyue Zhang; Li Piao; Siqing Wang; Ying Yue
Journal:  Oncol Lett       Date:  2021-04-29       Impact factor: 2.967

3.  High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids.

Authors:  Frank Antony; Cecilia Deantonio; Diego Cotella; Maria Felicia Soluri; Olga Tarasiuk; Francesco Raspagliesi; Fulvio Adorni; Silvano Piazza; Yari Ciani; Claudio Santoro; Paolo Macor; Delia Mezzanzanica; Daniele Sblattero
Journal:  Oncoimmunology       Date:  2019-06-04       Impact factor: 8.110

4.  Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.

Authors:  Guoqing Cai; Xiangdong Ma; Biliang Chen; Yanhong Huang; Shujuan Liu; Hong Yang; Wei Zou
Journal:  Tumour Biol       Date:  2016-04-08

5.  Comparison of clinical utility between neutrophil count and neutrophil-lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review.

Authors:  Naoko Komura; Seiji Mabuchi; Eriko Yokoi; Katsumi Kozasa; Hiromasa Kuroda; Tomoyuki Sasano; Yuri Matsumoto; Tadashi Kimura
Journal:  Int J Clin Oncol       Date:  2017-09-26       Impact factor: 3.402

6.  Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model.

Authors:  Jyothi Thyagabhavan Mony; Lixin Zhang; Tianzhou Ma; Shannon Grabosch; Tejas S Tirodkar; Joan Brozick; George Tseng; Esther Elishaev; Robert P Edwards; Xin Huang; Anda M Vlad
Journal:  Cancer Immunol Immunother       Date:  2015-05-22       Impact factor: 6.968

7.  Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells.

Authors:  Y You; Y Li; M Li; M Lei; M Wu; Y Qu; Y Yuan; T Chen; H Jiang
Journal:  Clin Exp Immunol       Date:  2017-10-23       Impact factor: 4.330

8.  The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms.

Authors: 
Journal:  Ann Surg Oncol       Date:  2020-04-13       Impact factor: 5.344

Review 9.  Niraparib: A Review in Ovarian Cancer.

Authors:  Young-A Heo; Sean T Duggan
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

10.  miR-197-3p reduces epithelial-mesenchymal transition by targeting ABCA7 in ovarian cancer cells.

Authors:  Weiquan Xie; Chengyu Shui; Xiping Fang; Yuqiu Peng; Li Qin
Journal:  3 Biotech       Date:  2020-08-04       Impact factor: 2.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.